| |  Online-Ressource |
|---|
| Verfasst von: | Sommerer, Claudia [VerfasserIn]  |
|---|
| | Schmitt, Anita [VerfasserIn] |
|---|
| | Hückelhoven-Krauss, Angela [VerfasserIn] |
|---|
| | Giese, Thomas [VerfasserIn] |
|---|
| | Bruckner, Thomas [VerfasserIn] |
|---|
| | Wang, Lei [VerfasserIn] |
|---|
| | Schnitzler, Paul [VerfasserIn] |
|---|
| | Meuer, Stefan [VerfasserIn] |
|---|
| | Zeier, Martin [VerfasserIn] |
|---|
| | Schmitt, Michael [VerfasserIn] |
|---|
| Titel: | Peptide vaccination against cytomegalovirus induces specific T cell response in responses in CMV seronegative end-stage renal disease patients |
|---|
| Verf.angabe: | Claudia Sommerer, Anita Schmitt, Angela Hückelhoven-Krauss, Thomas Giese, Thomas Bruckner, Lei Wang, Paul Schnitzler, Stefan Meuer, Martin Zeier and Michael Schmitt |
|---|
| E-Jahr: | 2021 |
|---|
| Jahr: | 6 February 2021 |
|---|
| Umfang: | 15 S. |
|---|
| Fussnoten: | Gesehen am 09.09.2021 |
|---|
| Titel Quelle: | Enthalten in: Vaccines |
|---|
| Ort Quelle: | Basel : MDPI, 2013 |
|---|
| Jahr Quelle: | 2021 |
|---|
| Band/Heft Quelle: | 9(2021), 2, Artikel-ID 133, Seite 1-15 |
|---|
| ISSN Quelle: | 2076-393X |
|---|
| Abstract: | Introduction: Cytomegalovirus (CMV) reactivation occurs in seronegative patients after solid organ transplantation (SOT) particularly from seropositive donors and can be lethal. Generation of CMV-specific T cells helps to prevent CMV reactivation. Therefore, we initiated a clinical phase I CMVpp65 peptide vaccination trial for seronegative end-stage renal disease patients waiting for kidney transplantation. Methods: The highly immunogenic nonamer peptide NLVPMVATV derived from CMV phosphoprotein 65(CMVpp65) in a water-in-oil emulsion (Montanide™) plus imiquimod (Aldara™) as an adjuvant was administered subcutaneously four times biweekly. Clinical course as well as immunological responses were monitored using IFN-γ ELISpot assays and flow cytometry for CMV-specific CD8+ T cells. Results: Peptide vaccination was well tolerated, and no drug-related serious adverse events were detected except for Grade I-II local skin reactions. Five of the 10 patients (50%) mounted any immune response (responders) and 40% of the patients presented CMV-specific CD8+ T cell responses elicited by these prophylactic vaccinations. No responders experienced CMV reactivation in the 18 months post-transplantation, while all non-responders reactivated. Conclusion: CMVpp65 peptide vaccination was safe, well tolerated, and clinically encouraging in seronegative end-stage renal disease patients waiting for kidney transplantation. Further studies with larger patient cohorts are planned. |
|---|
| DOI: | doi:10.3390/vaccines9020133 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.3390/vaccines9020133 |
|---|
| | Volltext: https://www.mdpi.com/2076-393X/9/2/133 |
|---|
| | DOI: https://doi.org/10.3390/vaccines9020133 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | CMV reactivation |
|---|
| | cytomegalovirus (CMV) |
|---|
| | phosphoprotein 65 (pp65) peptide vaccination |
|---|
| | renal transplantation |
|---|
| | specific T cells |
|---|
| K10plus-PPN: | 1753142679 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Peptide vaccination against cytomegalovirus induces specific T cell response in responses in CMV seronegative end-stage renal disease patients / Sommerer, Claudia [VerfasserIn]; 6 February 2021 (Online-Ressource)
